Gregory Mangum, DPM
Foot & Ankle Surgery · Houston, TXNPI 1336239359
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $564 of the $680 with a category attached, or 82.8%. 9 manufacturers reported payments, led by Smith+Nephew at 25.4% of the total. That places this record below the midpoint for foot & ankle surgery clinicians in TX, where the typical reported total is $3,901.
Across 23 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$173
- Zimmer Biomet$143
- Kerecis Limited$138
- Medline Industries LP$113
- Musculoskeletal Transplant Foundation Inc.$41
- Organogenesis Inc.$27
- plus $46 from 3 others
What the payments were for
- Food & beverage$56483%
- Education$11717%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 10 | $173 |
| Zimmer Biomet | 2 | $143 |
| Kerecis Limited | 2 | $138 |
| Medline Industries LP | 4 | $113 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $41 |
| Organogenesis Inc. | 1 | $27 |
| Medtronic | 1 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Lifenet Health | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$680 in reported general payments places this provider in the 15th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 16 | $527 |
| Terbinafine Hcl | 24 | $482 |
| Ketoconazole | 14 | $435 |
| Ammonium Lactate | 14 | $301 |
| Cefdinir | 14 | $288 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $78 |
| Tramadol Hcl | 12 | $60 |
| Meloxicam | 15 | $12 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Houston
- Kevin VarnerHouston$1.1M
- Sherman NaglerHouston$602K
- Abdul NurudeenHouston$404K
- Orlando RiveraHouston$384K
- Brian LepowHouston$309K
- Yueh LeeHouston$95K
- William GranberryHouston$84K
- Nathaniel AlabiHouston$71K
- Jorge MatukHouston$45K
- William McGarveyKaty$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.